Month of BID Pimecrolimus Best in Facial Seborrheic Dermatitis

This article originally appeared here.
Share this content:
Month of BID Pimecrolimus Best in Facial Seborrheic Dermatitis
Month of BID Pimecrolimus Best in Facial Seborrheic Dermatitis

MONDAY, June 19, 2017 (HealthDay News) -- Pimecrolimus 1 percent cream applied twice a day for four weeks seems to be the best regimen for patients with facial seborrheic dermatitis, according to a study published online June 7 in the Journal of Cosmetic Dermatology.

Juemin Zhao, M.D., from Fudan University in Shanghai, and colleagues examined the comparative efficacy of pimecrolimus 1 percent cream with different treatment regimens in 30 patients with facial seborrheic dermatitis. The regimens included treatment with topical pimecrolimus cream twice daily for two weeks then a moisturizer cream twice daily for two weeks (Group 1), pimecrolimus cream 1 percent twice daily for two weeks then once daily for two weeks (Group 2), and a consecutive course of pimecrolimus cream twice daily for four weeks (Group 3).

The researchers observed significant decreases in the clinical severity scores of all three regimens at week four (P < 0.01). Compared with groups 1 and 2, group 3 had a more remarkable improvement in total severity score (P < 0.05); in group 3 this effect was maintained to the end of the study. All three groups had significantly improved life quality at week four (P < 0.001), while no significant difference was seen between the groups in improvement of life quality.

"We recommend pimecrolimus 1 percent cream could be applied twice a day for 4 weeks to treat seborrheic dermatitis," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Osimertinib Tops Standard EGFR-TKI for EGFR NSCLC

Osimertinib Tops Standard EGFR-TKI for <i>EGFR</i>&#43; NSCLC

Significantly longer median progression-free survival for osimertinib in previously untreated NSCLC

Distinct Features for Drug Use-Related Endophthalmitis

Distinct Features for Drug Use-Related Endophthalmitis

Injection drug users have fewer comorbidities and more improvement in visual acuity after intervention

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Nonmedical use of prescription drugs linked to dating violence for male, female high school students

is free, fast, and customized just for you!

Already a member?

Sign In Now »